Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...